Policy | February 24, 2026
India shifts focus from 'Pharmacy of the World' to 'Global Innovation Hub', says Health Minister Nadda
Nadda underlined that India’s policy framework is aligned with this transformation
Nadda underlined that India’s policy framework is aligned with this transformation
The MoU lays the groundwork for deep academic and research collaboration in pharmaceutical technologies
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization
The agreement will see the two companies jointly develop and commercialise premium nutraceutical ingredients in advanced transdermal delivery formats
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
The acquisition marks the company’s strategic entry into the fast-growing Hormone Replacement Therapy (HRT) segment and significantly strengthens its gynaecology portfolio in India
BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
U.S. market achieved record quarterly sales of Rs. 3,113.2 crore ($350 million), a 54% YoY increase, accounting for 44% of global sales
Subscribe To Our Newsletter & Stay Updated
